Boston Scientific Corp (BSX) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Abbott Labs Price Target Cut by Analysts
Analysts responded to Abbott s reduced profit forecast, but they remain bullish because of Abbott s strong fundamentals. Shares firmed.
Author:
Abbott Laboratories (
The stock recently traded at $107.11, up 1.25%. It has dropped 2.2% over the past six months, after plummeting 9% on Tuesday following the profit forecast reduction.
As for the analysts, Morgan Stanley’s Cecilia Furlong lowered her price target to $126 from $140 but left her rating at overweight.
“While the post-COVID Dx [diagnosis] earnings void comes sooner than forecast, and while expectations will reset, reinvestment opportunities remain meaningful,” she said. “Base business trends are positive on recovery.”
Start Trading
Trading Derivatives carries a high level of risk to your capital and you should only trade with money you can afford to lose. Trading Derivatives may not be suitable for all investors, so please ensure that you fully understand the risks involved, and seek independent advice if necessary. A Product Disclosure Statement (PDS) can be obtained either from this website or on request from our offices and should be considered before entering into a transaction with us. Raw Spread accounts offer spreads from 0.0 pips with a commission charge of USD $3.50 per 100k traded. Standard account offer spreads from 1 pips with no additional commission charges. Spreads on CFD indices start at 0.4 points. The information on this site is not directed at residents in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
Operator
Good day, and thank you for standing by and welcome to the Inari Medical Inc. Q1 2021 earnings conference call.[Operator Instructions] I would now like to hand the conference over to your speaker today, Caroline Corner of investor relations. Please go ahead.
Caroline Corner
Investor Relations
Thank you, operator. Welcome to Inari s first-quarter 2021 earnings call. Joining me on today s call are Bill Hoffman, president and chief executive officer; and Mitch Hill, chief financial officer. For the Q&A session, we will also be joined by Drew Hykes, chief operating officer; and Dr.
Tom Tu, chief medical officer. This call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the markets in which Inari operates, trends and expectations for Inari s prod
Operator
Welcome to the iRhythm Technologies, Inc. Q1 2021 Earnings Conference Call. My name is Erin, and I ll be your operator for today s call. [Operator Instructions] Later, we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded. I ll now turn the call over to Leigh Salvo. Leigh, you may begin.
Leigh J. Salvo
Managing Director
Thank you all for participating in today s call. Joining me are Mike Coyle, CEO; Doug Devine, CFO; and Dan Wilson, EVP, Strategy, Corporate Development and Investor Relations. Earlier today, iRhythm released financial results for the first quarter ended March 31, 2021. A copy of the press release is available on the company s website. Before we begin, I d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Secur